Comparative Pharmacology
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus PROMETH FORTIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BROMPHENIRAMINE MALEATE versus PROMETH FORTIS.
BROMPHENIRAMINE MALEATE vs PROMETH FORTIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive antagonist of histamine at H1 receptor sites, suppressing histamine-induced vasodilation, increased capillary permeability, and bronchoconstriction.
Promethazine is a phenothiazine derivative that acts as a histamine H1 receptor antagonist, with additional anticholinergic, antiemetic, and sedative properties. It blocks histamine at H1 receptors, reducing allergic symptoms and motion sickness, and exerts antiemetic effects by blocking dopamine D2 receptors in the chemoreceptor trigger zone.
4 mg orally every 4-6 hours, not to exceed 24 mg/day. Alternatively, extended-release: 12 mg every 12 hours.
Adults: 12.5-25 mg intramuscular or intravenous every 4-6 hours as needed for nausea. For severe nausea up to 50 mg IM/IV. Maximum single dose 50 mg, maximum daily dose 200 mg.
None Documented
None Documented
Terminal half-life 22-25 hours; prolonged in hepatic impairment or elderly (up to 40 hours).
Terminal elimination half-life: 9–16 hours (mean ~12 hours). In children and elderly, half-life may be prolonged (up to 20 hours).
Renal (85-90% as metabolites, 5-10% unchanged); biliary/fecal <5%.
Primarily renal as inactive metabolites; <1% excreted unchanged. Total elimination: renal ~70%, fecal ~30%.
Category C
Category C
Antihistamine
Antihistamine